• About
  • Overview
  • Management
    • Dr. Joe Lewis
    • Dr. Bernd Janssen
    • Dr Fiona McLaughlin
    • Sally-Anne Watson
  • Supervisory Board
  • Scientific Advisory Board
  • Investors
• Programs
  • Mechanism of Action
  • Technology
  • Products
  • Technology Fact Sheet
• News
  • Latest News
  • Upcoming Events
  • Download Area
• Careers
  • Vacancies
• Contact
  • Contact
• Home
  • Home

Overview

Elara Pharmaceuticals is focusing on the development of novel treatments for malignant diseases through the development of dual mechanism inhibitors. The company's lead series targets the so-called hypoxia signaling pathway and in parallel induces apoptosis.

Elara's lead product has entered preclinical development in 2010. In animal models of cancer it demonstrates good efficacy and a favorable pharmacokinetic and tolerability profile. It has demonstrated broad activity against both solid and hematological malignancies.

Two novel series targeting the same pathway are currently in lead optimization.

Further information is available in the Products & Technology sections.